Expression of heat shock protein Hsp 27 in ovarian carcinoma

Objective: The aim of the present study was to determine the expression of heat shock protein 27 (Hsp 27) in patients with ovarian carcinoma and its relationship with clinical and histopathological characteristics. Materials and Methods: Cross-sectional study in patients diagnosed with ovarian carcinoma. From paraffin blocks with tumor material, archived in the pathology services of the San Jose and Infantil Unversitario de San Jose hospitals since 2013 to 2016 the expression of Hsp 27 was analyzed using a semi-quantitative measurement method. Patients´ clinical records were reviewed to analyze clinical and histopathological characteristics. Results: Immunohistochemistry was performed on 31 patients. Hsp 27 immunostaining was positive in more than 50% of tumor cells in 17 (54.8%) cases. The intensity of Hsp 27 expression was strong in 13 (41.9%) cases. The most frequent location was membranous and cytoplasmatic in 25 (80.6%). The characterization of patients with intensity of 3+ occurred mainly in high-grade serous papillary stage IIIC carcinomas. Conclusion: A stronger Hsp 27 expression occurred mainly in patients with high-grade serous, histology, advanced FIGO stage and in whom optimal or complete cytoreduction could not be performed.

Ovarian cancer; Heat shock protein 27; Neoplasia.

[1] Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A.: “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA Cancer J. Clin., 2018, 68, 394.

[2] Quirk J.T., Natarajan N.: “Ovarian cancer incidence in the United States, 1992–1999”. Gynecol. Oncol., 2005, 97, 519.

[3] Heintz A.P.M., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Creasman W.T., et al.: “Carcinoma of the ovary”. Int. J. Gynecol. Obstet., 2003, 83, 135.

[4] Geisler J.P., Geisler H.E., Tammela J., Wiemann M.C., Zhou Z., Miller G.A., et al.: “Heat shock protein 27: an independent prognostic indicator of survival in patients with epithelial ovarian carcinoma”. Gynecol. Oncol., 1998, 69, 14.

[5] Hartl F.U.: “Molecular chaperones in cellular protein folding”. Nature, 1996, 381, 571.

[6] Ciocca D.R., Calderwood S.K.: “Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications”. Cell Stress Chaperones, 2005, 10, 86.

[7] Samali A., Orrenius S.: “Heat shock proteins: regulators of stress re-sponse and apoptosis”. Cell Stress Chaperones, 1998, 3, 228.

[8] Bakthisaran R., Tangirala R., Rao C.M.: “Small heat shock proteins: Role in cellular functions and pathology”. Biochim. Biophys. Acta, 2015, 1854, 291.

[9] Arts H.J., Hollema H., Lemstra W., Willemse P.H., De Vries E.G., Kampinga H.H., et al.: “Heat-shock-protein-27 (Hsp 27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis”. Int. J. Cancer., 1999, 84, 234.

[10] Geisler J.P., Geisler H.E., Tammela J., Miller G.A., Wiemann M.C., Zhou Z.: “A study of heat shock protein 27 in endometrial carcinoma”. Gynecol. Oncol., 1999, 72, 347.

[11] Geisler J.P., Tammela J.E., Manahan K.J., Geisler H.E., Miller G.A., Zhou Z., et al.: “HSP 27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up”. Eur. J. Gynaecol. Oncol., 2004, 25, 165.

[12] Elpek G.O., Karaveli S., Simşek T., Keles N., Aksoy N.H.: “Expres-sion of heat-shock proteins Hsp 27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries”. APMIS., 2003, 111, 523.

[13] Vidyasagar A., Wilson N.A., Djamali A.: “Heat shock protein 27 (HSP 27): biomarker of disease and therapeutic target”. Fibrogenesis Tissue Repair, 2012, 5, 7.

[14] Lianos G.D., Alexiou G.A., Mangano A., Rausei S., Boni L., Dionigi G., et al.: “The role of heat shock proteins in cancer”. Cancer Lett., 2015, 360, 114.

[15] Cohen M., Dromard M., Petignat P.: “Heat shock proteins in ovarian cancer: a potential target for therapy”. Gynecol. Oncol., 2010, 119, 164.

[16] Choi D.H., Ha J.S., Lee W.H., Song J.K., Kim G.Y., Park J.H., et al.: “Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells”. FEBS Lett., 2007, 581, 1649.

[17] Garrido C., Fromentin A., Bonnotte B., Favre N., Moutet M., Arrigo A. P., et al.: “Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones”. Cancer Res., 1998, 58, 5495.

[18] Suzuki H., Sugimura H., Hashimoto K.: “Overexpression of heat shock protein 27 is associated with good prognosis in the patient with oral squamous cell carcinoma”. Br. J. Oral Maxillofac. Surg., 2007, 45, 123.

[19] Zagorianakou N., Ioachim E., Mitselou A., Kitsou E., Zagorianakou P., Makrydimas G., et al.: “Immunohistochemical expression of heat shock protein 27, in normal hyperplastic and neoplastic endometrium: correlation with estrogen and progesterone receptor status, p53, pRb and proliferation associated indices (PCNA, MIB1)”. Eur. J. Gynaecol. Oncol., 2003, 24, 299.

[20] Dobo C., Stavale J.N., Lima FeO., Ribeiro D.A., Arias V, Gomes T.S., et al.: “HSP 27 is commonly expressed in cervical intraepithelial le-sions of Brazilian women”. Asian Pac. J. Cancer Prev., 2013, 14, 5007.

[21] Song T.F., Zhang Z.F., Liu L., Yang T., Jiang J., Li P.: “Small inter-fering RNA-mediated silencing of heat shock protein 27 (HSP 27) In-creases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910)”. J. Int. Med. Res., 2009, 37, 1375.

[22] Zhao M., Shen F., Yin Y.X., Yang Y.Y., Xiang D.J., Chen Q.: “Increased expression of heat shock protein 27 correlates with peritoneal metastasis in epithelial ovarian cancer”. Reprod. Sci., 2012, 19, 748.

[23] Zhao M., Ding J.X., Zeng K., Zhao J., Shen F., Yin Y.X., et al.: “Heat shock protein 27: a potential biomarker of peritoneal metastasis in epithelial ovarian cancer?” Tumour Biol., 2014, 35, 1051.

[24] Langdon S.P., Rabiasz G.J., Hirst G.L., King R.J., Hawkins R.A., Smyth J.F., et al.: “Expression of the heat shock protein HSP 27 in human ovarian cancer”. Clin. Cancer Res., 1995, 1, 1603.

[25] Vendetti S., Cicconi R., Piselli P., Vismara D., Cassol M., Delpino A.: “Induction and membrane expression of heat shock proteins in heat-treated HPC-4 cells is correlated with increased resistance to LAK-mediated lysis”. J. Exp. Clin. Cancer Res., 2000, 19, 329.

[26] Lu H., Sun C., Zhou T., Zhou B., Guo E., Shan W., et al.: “HSP27 Knockdown Increases Cytoplasmic p21 and Cisplatin Sensitivity in Ovarian Carcinoma Cells”. Oncol. Res., 2016, 23, 119.

[27] Olejek A., Damasiewicz-Bodzek A., Bodzek P., Wielkoszyński T., Zamłyński J., Stołtny P., et al.: “Concentrations of antibodies against heat shock protein 27 in the sera of women with ovarian carcinoma”. Int. J. Gynecol. Cancer., 2009, 19, 1516.